Currently Viewing:
Genitourinary Cancers Symposium
Dr Donna Hansel Discusses Challenges When Treating Advanced Bladder Cancer
May 04, 2018
Dr Joe O'Sullivan: We Are Getting Better at Treating Prostate Cancer Earlier
April 29, 2018
Dr Joe O'Sullivan: Numerous Prostate Cancer Therapies Is a Challenge for Clinical Trials
April 19, 2018
Dr Joe O'Sullivan Explains Education of Patients and Physicians on Molecular Therapies
April 03, 2018
Dr Donna Hansel on Targeting mTOR in Advanced Bladder Cancer
March 28, 2018
Dr Christopher Kane Explains How MRI Is Influencing Prostate Cancer Diagnosis
February 28, 2018
Pembrolizumab Associated With Increased Overall Survival in Patients With Urothelial Cancer
February 14, 2018
Currently Reading
Dr Sumit Subudhi Discusses Immune Checkpoint Inhibitors in Prostate Cancer
February 11, 2018
Medicaid Expansion Led to Earlier Stage at Diagnosis of Testicular Cancer
February 10, 2018
Daily IGRT in Prostate Cancer Reduces Risk of Recurrence, Increases Risk of Second Cancer
February 10, 2018
Dr Christopher Kane on Robotic Procedures in Prostate Cancer
February 10, 2018
Use of Biomarkers to Identify Patients, Therapies for Neoadjuvant Chemotherapy
February 10, 2018
Combining Radiation and Immunotherapy in Patients With Bladder Cancer
February 09, 2018
Guidelines for Management of Muscle-Invasive Bladder Cancer
February 09, 2018
Is There Evidence for Local Treatment for Newly Diagnosed Metastatic Prostate Cancer?
February 09, 2018
Dr Joe O'Sullivan on Molecular Therapies in Prostate Cancer
February 09, 2018
Osteomimicry May Contribute to Uptake of Radium-223 Within Bone Metastases for Patients With mCRPC
February 09, 2018
Apalutamide Significantly Improved Metastasis-Free Survival in Men With nmCRPC
February 09, 2018

Dr Sumit Subudhi Discusses Immune Checkpoint Inhibitors in Prostate Cancer

In prostate cancer, we're using combinations by looking to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy, said Sumit Subudhi, MD, PhD, genitourinary medical oncology, MD Anderson Cancer Center.


In prostate cancer, combination therapies are being used to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy, said Sumit Subudhi, MD, PhD, genitourinary medical oncology, Cancer Medicine, MD Anderson Cancer Center.

Transcript (slightly modified)

Prostate cancer has had lower response rates to single-agent immune checkpoint inhibitors than other cancers. How are you working towards understanding who will have the best response to these inhibitors?

It’s been a real struggle to get the response we see in malignancies such as melanoma, kidney, and bladder. What we’re starting to understand is that the prostate cancer tumor microenvironment is just really an immunosuppressive 1, and so the strategies we’re using now is using combinations, and rational combinations, by looking to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy.

So, for example we’ve completed a trial where we were doing ipilimumab plus anti- PD-1, and the reason for that was after giving 2 doses of ipilimumab, we found that the tumor microenvironment upregulates both PD-1 and PD-L1, so by doing the combination, we should see better responses, and so far it looks like the early signals show that. We’re getting better response, but not as well as we see in melanoma.

What we’re going to have to do is find out who are these patients that actually respond so that we can enrich that population and then also better understand why the other patients are not responding.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!